NCT01856426View on ClinicalTrials.gov

Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

October 31, 2015

Conditions
Hepatitis C
Interventions
DRUG

EDP239

DRUG

Placebo

Trial Locations (5)

20099

Investigative Site, Hamburg

33169

Investigative Site, Miami

60590

Investigative Site, Frankfurt

78215

Investigative Site, San Antonio

84123

Investigative Site, Murray

Sponsors
All Listed Sponsors
lead

Enanta Pharmaceuticals, Inc

INDUSTRY